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TNF-a on central insulin and leptin signaling in rats pre-treated with PTP1B-ASO. The icv infusion of
TNF-a-induced an increase in PTP1B protein expression and activity, and attenuated insulin and lep-
tin sensitivity and signaling in the hypothalamus. However, TNF-a was able to completely blunt the
leptin and insulin effect in rats treated with PTP1B-ASO, suggesting that TNF-a does not require
PTP1B to fully attenuate the leptin and insulin effects. In addition, our data also show that other
mechanisms of insulin and leptin resistance are activated in the hypothalamus by TNF-a.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Obesity is accompanied by resistance to insulin and leptin, key
hormones regulating glucose homeostasis and body weight [1],
but the molecular mechanisms that account for these hormonal
resistances are not completely known. The protein tyrosine phos-
phatase – PTP1B is one of the major negative regulators of insulin
and leptin signaling, acting to dephosphorylate the insulin receptor
and the leptin receptor-associated Janus kinase 2 [2,3]. In previous
studies, we and others demonstrated that a selective decrease in
hypothalamic PTP1B protein resulted in decreased food intake,
reduced body weight, reduced adiposity after high-fat feeding and
improved insulin and leptin action and signaling [4,5]. Other stud-
ies demonstrated that the PTP1B deﬁciency enhances insulin
signaling, in skeletal muscle and liver, reduces adiposity and pro-
tected from diet-induced obesity [5–10].
In most studies in obese animals, in different tissues, an in-
crease in phosphotyrosine phosphatase activity is well character-
ized, and speciﬁcally an increase in PTP1B expression and
activity. It is important to mention that there is a clear correla-chemical Societies. Published by E
eptor substrate; icv, intracer-
sphatase 1B
. Saad).tion between the increase in PTP1B tissue level with enzyme
activity [11–13,4], suggesting that the regulation of PTP1B pro-
tein expression as a major mechanism mediating increased
PTP1B activity. However the mechanisms that inﬂuence PTP1B
level/activity in obesity are not completely known. In the past
10 years it became evident that in obesity and type 2 diabetes
there is a subclinical inﬂammatory process, which has an
important role in the insulin resistance in these situations. Ele-
vated inﬂammatory cytokines such as tumor necrosis factor a
(TNF-a), IL1b, and IL6 are seen in obesity and may play a direct
role in development of obesity-associated insulin resistance
[14–16].
In peripheral tissues TNF-a impairs insulin signal transduction
through the activation of serine kinases, such as JNK and IKKb
[17–19]. Moreover, a recent study has shown that adipose tissue
inﬂammation and the pro-inﬂammatory cytokine, TNF-a, can reg-
ulate PTP1B expression in vivo [20]. Since TNF-amay, under differ-
ent circumstances, antagonize the effects of insulin and leptin in
the hypothalamus we decided to evaluate the effects of TNF-a on
the regulation of PTP1B in the hypothalamus, and also whether this
cytokine is able to antagonize insulin and leptin action and signal-
ing, after a reduction in PTP1B expression in this tissue. Knowledge
of the regulation of PTP1B in the central nervous system may show
metabolic and functional importance in the regulation of insulin
and leptin signaling in the brain, providing substrate for new ther-
apeutic approaches.lsevier B.V. All rights reserved.
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2.1. Antibodies, chemicals, buffers and oligonucleotides
Antibodies anti-IR, IRS-1, Jak-2, Stat3, anti-phospho-JNK
(phosphorylated at Thr183 and Tyr185), anti-phospho-
IRS-1(Ser307), anti-phospho-IKKb (phosphorylated at Ser181) and
anti-phosphotyrosine were purchased from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA). Anti-phosphoserine antibody was
purchased from Zymed Laboratories Inc., San Francisco, CA. Anti-
phospho-Akt (rabbit polyclonal, recognizing Akt phosphorylated
at Ser473) was purchased from Upstate Biotechnology (Charlottes-
ville, VA, USA) Anti-PTP1B (AB-1 mouse polyclonal) was purchased
from Calbiochem (La Jolla, CA). pp60src C-terminal phosphoregula-
tory peptide (TSTEPQpYQPGENL; where pY represents phosphoty-
rosine and Biomol Green reagent were purchased from Biomol
(Plymouth Meeting, PA). Reagents for SDS/PAGE and immunoblot-
ting were obtained from Bio-Rad (Richmond, CA, USA). Tris
[hydroxymethyl] amino-methane (Tris), Hepes, phenylmethysulfo-
nyl ﬂuoride (PMSF), aprotinin, dithiothreitol (DTT), Triton X-I00,
glycerol, Tween 20, bovine serum albumin (BSA, fraction V) and
angiotensin II were from Sigma Chemical CO. (St. Louis, MO,
USA). Protein A-Sepharose 6 MB was from Pharmacia (Uppsala,
Sweden), nitrocellulose membranes Human recombinant insulin
was from Eli Lilly Co. (Indianapolis, IN, USA). Leptin was from
Calbiochem (San Diego, CA, USA). Ketamine hydrochloride was
from Fort Dogde Laboratories Inc. (Fort Dodge, IA, USA). Sodium
thiopental was from Abbout Laboratories (North Chicago, Illinois,
USA). Antisense phosphorthioate oligonucleotides speciﬁc for
PTP1B (50-CCA ACA GCA CTT T-30) was produced by Invitrogen
Corp. (Carlsbad, CA). Mouse recombinant TNF-a was from Calbio-
chem (Darmstadt, Germany).3. Experimental animals
Eight-week old male Wistar rats (Rattus norvegicus) from the
University of Campinas Central Animal Breeding Center were
used in the experiments. The rats were allowed access to stan-
dard rodent chow and water (ad libitum). Food was withdrawn
12 h before the experiments. All experiments were conducted
according to the principles and procedures described by the
NIH Guidelines for the Care and Use of Section 3 and were ap-
proved by the State University of Campinas Ethical Committee.
In all experiments, the rats were cannulated intracerebroventri-
cularly (icv) and submitted to treatment with PTP1B-ASO (accom-
panied or not by saline, insulin, leptin, TNF-a or combinations of
TNF-a with insulin or leptin, according to the protocols described
below.
3.1. Intracebroventricular cannulation
All rats were stereotaxically instrumented using a Stoelning
stereotaxic apparatus, according to a previously described method
[21]. Cannula efﬁciency was tested 1 week after cannulation by
the evaluation of the drinking response elicited by icv angiotensin
II [22].
3.2. Phosphorthioate-modiﬁed oligonucleotide treatment
The sequences of antisense phosphorothioate oligonucleotides,
speciﬁc for PTP1B 50-CCA ACA GCA CTT T-30), were selected among
three unrelated pairs of oligonucleotides on the basis of their abil-
ity to block PTP1B protein expression, as evaluated by immuno-
blotting total protein extracts of hypothalamus using speciﬁc
anti-PTP1B antibody.The antisense oligonucleotide sequences were submitted to
BLAST analyses (www.ncbi.nlm.nih.gov) and matched only for
the Rattus norvegicus PTP1B coding sequence. Rats were cannulat-
ed, housed in individual cages and treated with saline or PTP1B
antisense oligonucleotide (PTP1B-ASO). PTP1B-ASO was diluted
in TE buffer (10 mM Tris–HCl, 1 mM EDTA) and treatment was
achieved by icv infusions, twice a day (8:00 h/18:00 h) with a total
vol of 2.0 ll per dose (4.0 nmol/ll) for 4 days.
3.3. Protocol for food ingestion determination
Rats cannulated icv were treated with PTP1B-ASO or saline
twice a day (8:00 h/18:00 h) with a total vol of 2.0 ll per dose
(4.0 nmol/ll) for 4 days. At the end of the fourth day, rats were
treated icv with insulin (2.0 ll, 106 M), leptin (2.0 ll, 106 M),
TNF-a (2.0 ll, 1012 M), saline or with combinations of TNF-a
(2.0 ll, 1012 M) with insulin (2.0 ll, 106 M) or leptin (2.0 ll,
106 M). Food ingestion was determined over the next 12 h.
3.4. Tissue extraction, immunoblotting and immunoprecipitation
Rats pre-treated with PTP1B-ASO or saline for 4 days were
anesthetized with sodium thiopental and, as soon as anesthesia
was assured by the loss of pedal and corneal reﬂexes, the rats were
subjected to craniotomy 15 min after the initial insulin (2.0 ll,
106 M), leptin (2.0 ll, 106 M) or saline (2.0 ll) and 4 h after the
initial TNF-a infusion. The hypothalami were obtained and homog-
enized in freshly prepared ice-cold buffer (1% Triton X-100,
100 mM Tris, pH 7.4, 100 mM sodium pyrophosphate, 100 mM so-
dium ﬂuoride, 10 mM EDTA, 10 mM sodium vanadate, 2 mM PMSF,
and 0.01 mg aprotinin/ml). Insoluble material was removed by
centrifugation (15 000g rpm) for 40 min at 4 C. The protein con-
centration of the supernatants was determined by the Bradford dye
binding method [23]. Aliquots of the resulting supernatants con-
taining 2.0 mg of total protein were used for immunoprecipitation
with speciﬁc antibodies, at 4 C overnight, followed by addition of
protein A-Sepharose 6 MB for 2 h. The pellets were washed three
times in ice-cold buffer (0.5% Triton X-100, 100 mM Tris, pH 7.4,
10 mM EDTA, and 2 mM sodium vanadate) and then resuspended
in Laemmli sample buffer [24] and boiled for 5 min, after which
they were subjected to SDS–PAGE in a miniature slab gel apparatus
(Mini-Protean). For total extracts, 0.2 mg of protein was separated
by SDS–PAGE. Electrotransfer of proteins from the gel to nitrocel-
lulose was performed for 120 min at 120 V in a Bio-Rad Mini-
Protean transfer apparatus. Non-speciﬁc protein binding to the
nitrocellulose was reduced by pre-incubating the ﬁlter for 2 h in
blocking buffer (5% non-fat dry milk, 10 mM Tris, 150 mM NaCl,
0.02% Tween 20) [25]. The nitrocellulose blot was incubated with
speciﬁc antibodies overnight at 4 C and then incubated with
125I-labeled protein A. Results were visualized by autoradiography
with pre-ﬂashed Kodak XAR ﬁlm. Band intensities were quantiﬁed
by optical densitometry of developed autoradiographs (Scion
Image software, ScionCorp).
3.5. Protein tyrosine phosphatase activity assay
The in vitro PTP1B activity assay was conducted based on a
protocol previously described by Taghibiglou et al. [13]. Hypotha-
lami were removed and homogenized in solubilization buffer
containing 1% Triton X-100, 20 mM, Tris (pH 7.6), 5 mM EDTA,
2 mM PMSF and 0.1 mg aprotinin/mL, 1 mM EGTA and 130 mM
NaCl. Lysates were centrifuged (15 000g rpm, 40 min, 4 C) and
the supernatants were collected for immunoprecipitation with
anti-PTP1B antibody, as described previously. Immunoprecipitate
was washed in PTP assay buffer (100 mM HEPES (pH 7.6), 2 mM
EDTA, 1 mM dithiothreitol, 150 mM NaCl, 0,5 mg/mL bovine serum
T
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P.K. Picardi et al. / FEBS Letters 584 (2010) 3179–3184 3181albumin). The pp60c-src C-terminal phosphoregulatory peptide
(TSTEPQpYQPGENL) was added to a ﬁnal concentration of
200 lM in a total reaction volume of 60 ll in a PTP assay buffer
for immunoprecipitation. The activity of total extracts (125 lg)
was measured in the same manner in a total reaction volume of
60 ll in a PTP assay buffer, adding the peptide to a ﬁnal concentra-
tion 200 lM. The reaction was then allowed to proceed for 1 h at
30 C. At the end of the reaction, 40 ll aliquots were placed into
96-well plates, 100 ll of Biomol Green reagent (Biomol) was
added, and absorbance was measured at 660 nm.
3.6. Data presentation and statistical analysis
Data were expressed as means ± S.E.M. accompanied by the
indicated number of independent experiments. For statistical anal-
ysis, the groups were compared using a two way ANOVA with the
Bonferroni test for post hoc comparisons. The level of signiﬁcance
adopted was P < 0.05.ti
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Fig. 1. Activation of PTP1B by TNF-a in hypothalamus. Immunoblotting with anti-
PTP1B antibody of whole tissue extracts from hypothalamus of rats treated with
TNF-a (106 M) for 1, 2 and 4 h (A); Immunoprecipitate with anti-PTP1B antibody
of whole tissue extracts from hypothalamus of rats treated with TNF-a (106 M) for
4 h and followed by immunoblotting with antibody anti-phosphoserine (B) or anti-
phoshotyrosine (C); Total PTPase activity and PTPase activities in immunoprecip-
itates were assayed by incubation with the pp60c-src C-terminal phosphoregula-
tory peptide (TSTEPQpYQPGENL). PTPase activity in PTP1B immunoprecipitates (D),
Total PTPase activity in hypothalamus (E); in all experiments, n = 6; P < 0.05; *, vs.
saline; Results are presented as means ± S.E.M.4. Results
4.1. Activation of PTP1B by TNF-a in the hypothalamus
TNF-a inhibits insulin action in vitro and in vivo by altering
expression or activity of multiple proteins in the insulin signaling
pathway in cells [15,26,27]. The up-regulation of PTP1B expression
was recently found in cells treated with TNF-a [28]. To evaluate the
ability of TNF-a to modulate PTP1B expression and activity in
hypothalamus, icv cannulated rats were treated with a single dose
of TNF-a (2.0 ll, 1012 M) or saline and the hypothalami were
obtained 1, 2 and 4 h after the initial TNF-a infusion. As shown
in Fig. 1A, the expression of PTP1B increased by 50% (P < 0.05) at
2 h after treatment with TNF-a, and a more marked increase was
observed after 4 h (148% – P < 0.05).
To address the nature of the change in PTP1B that accompa-
nies the increase in expression in response to TNF-a, hypotha-
lami extracts were used to examine the phosphoserine and
phosphotyrosine content of PTP1B by immunoblotting with
anti-phosphoserine and anti-phosphotyrosine antibodies. Using
the peak response at 4 h following TNF-a administration icv,
the phosphoserine content of PTP1B increased signiﬁcantly by
150% (P < 0.05) and phosphotyrosine content decreased by about
50%, respectively (P < 0.05) (Fig. 1B and C). We next investigated
whether the total PTPase and PTPase, related to PTP1B activities,
accompanies the increase in the expression of PTP1B in response
to TNF-a. The administration of TNF-a-induced increases in the
phosphatase activity of PTP1B and in total phosphatase activity
of 147% (P < 0.05) and 145% (P < 0.05), respectively (Fig. 1D and
E).
4.2. Activation of insulin action by hypothalamic reduction of PTP1B in
the presence of TNF-a
To investigate whether PTP1B may mediate the effect of TNF-a
effect on food ingestion, rats were icv cannulated and, after the
recovery period, they were treated for 4 days with PTP1B-ASO or
saline, and on the 4th day, both groups were treated with
1012 M TNF-a. The potency of PTP1B-ASOwas tested in a dose–re-
sponse experiment. Two daily doses of 4 nmol PTP1B were sufﬁ-
cient to inhibit PTP1B expression by 70% in control rats (Fig. 2A).
TNF-a alone promoted no change in food intake (18.1 ± 1.3 g),
when compared with rats treated with saline (22.5 ± 0.3 g). As ex-
pected in animals treated with PTP1B-ASO, there was a marked
reduction in food intake when compared with saline or TNF-a
and, after infusion of TNF-a in these animals the, reduction in foodintake was less evident (Fig. 2B), suggesting that this cytokine may
be acting through a pathway that does not involve PTP1B.
We next decided to evaluate whether TNF-a may modulate
insulin effects after the reduction of PTP1B. For this purpose, rats
were icv cannulated and, after the recovery period, they were trea-
ted for 4 days with PTP1B-ASO or saline and, on the 4th day, both
groups were treated with insulin 106 M alone or TNF-a, followed
by insulin. Control rats consumed 20.1 ± 0.5 g of chow. Fig. 2C
shows that the infusion of insulin promoted signiﬁcant reductions
in food intake to 8.3 ± 0.7 g (P < 0.05 compared with saline). The
administration of TNF-a plus insulin partially reversed the anorex-
igenic effects of insulin (TNF-a plus insulin 12.4 ± 0.8 g  insulin
8.3 ± 0.7 g P < 0.05) . Fig. 2D shows that the treatment with
PTP1B-ASO decreased food intake to 10 ± 0.8 g (P < 0.05 compared
with the non-treated rats). PTP1B-ASO potentiated insulin-induced
suppression of food ingestion to 3.8 ± 0.2 g. However, insulin-in-
duced suppression of food intake in PTP1B-ASO, treated animals
was partially impaired by TNF-a, suggesting that TNF-a may have
other mediators besides PTP1B.
Insulin promoted signiﬁcant increases in the Tyr-phosphoryla-
tion of IR, IRS-1 and increased Ser473-phosphorylation of Akt. The
co-injection of TNF-a with insulin attenuated insulin-stimulated
IR, IRS-1 tyrosine phosphorylation and Akt serine phosphorylation.
We explored whether the deleterious effect of TNF-a may be re-
versed through the reduction of hypothalamic PTP1B. Rats treated
with PTP1B-ASO presented a signiﬁcant increase in insulin-in-
515
10
0
25
20
30
035
030
025
020
150
50
0
100
RS
e
p
s
r
I
-1
ty
ro
sin
ho
ph
o
yl
at
io
n
A
b
n
(
r
itr
ar
y
u
its
)
: N Blot  pJ K
h
IR
S-
1
se
rin
e
ph
o
sp
or
yl
at
io
n
A
y
(
rbi
tra
r
u
n
its
)
IP IRS : e: -1 Blot  p-S r307
Insulin
PTP1B-ASO
T FN -α
JN
K
ph
os
ph
or
yl
at
io
n
(T
hr
/T
yr
)
(A
rbi
tra
ry
u
n
its
)
- - +
- - -
- + +
-
+
+
+
+
+
Fo
o
d 
in
ta
ke
 (g
)
Fo
o
d 
in
ta
ke
 (g
)
Fo
o
d 
in
ta
ke
 (g
)
IP IR Blot  p-Tyr: :
250
200
150
50
0
100
IR
 ty
ro
sin
e 
ph
os
ph
or
yl
at
io
n
(A
rbi
tra
ry 
un
its
)
 Bl : pJNot K
IK
K
β
se
rin
e
ph
o
sp
ho
ry
la
tio
n
(A
rbi
tra
ry
un
its
)
IP IRS-1 Blo : p-Ser 307: t
IP IR Blot  p-Tyr: : IP:IRS-1 Blot  p-Tyr:
250
200
150
50
0
100
350
300
250
200
150
50
0
100
 Blot: p-AKT
A
K
T
se
rin
e
ph
o
sp
ho
ry
la
tio
n
(A
rb
itr
ar
y
u
n
its
)
250
200
150
50
0
100
350
300
250
200
150
50
0
100
ot TBl : p-AK
250
200
150
50
0
100
350
300
250
200
150
50
0
100
In ulins
T FN -α
- + - +
- - + +
250
200
150
50
0
100
βBlot: pIKK
3 05
3 00
2 05
2 00
1 05
50
0
1 00
ot: KKβBl  pI
250
200
150
50
0
100
3 05
3 00
2 05
2 00
1 05
50
0
1 00
: -1 Blot  p-TIP IRS : yr
Insulin
PT 1B ASOP -
FTN -α
- - +
- - -
- + +
-
+
+
+
+
+
n linI su
T FN -α
- + - +
- - + +
Insulin
PTP1B-ASO
T FN -α
- - +
- - -
- + +
-
+
+
+
+
+
Insulin
FTN -α
- + - +
- - + +
Insulin
BPTP1 -ASO
T FN -α
- - +
- - -
- + +
-
+
+
+
+
+
Insulin
FTN -α
- + - +
- - + +
In ulins
PTP1B ASO-
FTN -α
- - +
- - -
- + +
-
+
+
+
+
+
Insulin
TNF-α
- + - +
- - + +
Insulin
PTP1B-ASO
T FN -α
- - +
- - -
- + +
-
+
+
+
+
+
In ulins
T FN -α
- + - +
- - + +
Insulin
FTN -α
n linI su
PTP1B ASO-
FTN -α
C D
E F G H
I J K L
M N O P
- + +
-
- +
-
- +
- - -
- + +
+
+
+
5
15
10
0
25
20
30
5
15
10
0
25
20
30
A
PT
P1
B
x
pr
s
o
e
e
si
n
A
r
i
a
y
n
it
(
bt
r
r
u
s)
0.5
50
150
100
0
200
otBl : PTP1B
1 2 40
*
*
B
PTP1B ASO-
TNF-α - + +
- - +
n )PTP1B -ASO( M
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(4.0 nmol/ll) for 4 days. The potency of PTP1B-ASO was tested in a dose–response experiment (0.5, 1, 2 and 4 nM) (A). Food ingestion was determined after icv infusion with
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3182 P.K. Picardi et al. / FEBS Letters 584 (2010) 3179–3184duced IR, IRS-1 tyrosine phosphorylation, and Akt serine
phosphorylation. The reduced hypothalamic PTP1B only partially
reversed the effect of TNF-a on insulin signaling, at the level of
insulin-induced phosphorylation/activation of IR, IRS-1, and Akt
(Fig. 2E–J).Activation of the c-Jun N-terminal kinase (JNK) and IKKb by
TNF-a inhibits insulin signaling, at least in part, by stimulating
phosphorylation of insulin receptor substrate 1 (IRS-1) at Ser307.
We then investigated whether these mechanisms were also in-
volved in the effect of TNF-a on the insulin signaling pathway.
P.K. Picardi et al. / FEBS Letters 584 (2010) 3179–3184 3183Our results showed that TNF-a activates JNK and IKKb. There were
no differences in the insulin-stimulated phosphorylation of JNK,
IKKb and IRS-1-Ser307 of rats treated with PTP1B-ASO as com-
pared with rats that were not treated (Fig. 2K–P).
4.3. Activation of leptin action by hypothalamic reduction of PTP1B in
the presence of TNF-a
We evaluated the effects of the reduction of the hypothalamic
PTP1B, in the presence of TNF-a, on physiological and molecular
events controlled by leptin. For this purpose, rats were icv cannu-
lated and, after the recovery period, were treated for 4 days with
PTP1B-ASO or saline. On the 4th day both groups were treated with
106 M leptin alone or TNF-a, followed by leptin. Control rats con-
sumed 21.1 ± 0.5 g of chow. As shown in Fig. 3A, leptin promoted
signiﬁcant reductions in spontaneous food intake to 3.5 ± 1.0 g
(P < 0.05 compared with saline). The administration of TNF-a, fol-
lowed by leptin, attenuated leptin-inhibition of food intake to
13.3 ± 0.6 g (P < 0.05 compared with leptin – Fig. 3A). Fig. 3B showsI :Jak-2 Blo -TyrP t: p
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Fig. 3. Activation of leptin action by hypothalamic reduction of PTP1B in the
presence of TNF-a. Food ingestion was determined after icv infusion with TNF-a
(2.0 ll, 1012 M), leptin (2.0 ll, 106 M) or leptin plus TNF-a in rats pre-treated
with saline (A) or PTP1B-ASO (B); n = 15. To evaluate the leptin signaling, rats pre-
treated with PTP1B-ASO or saline for 4 days were anesthetized and subjected to
craniotomy 15 min after the initial leptin (106 M) or saline icv infusion and 4 h
after the initial TNF-a icv infusion; n = 6. The hypothalami were obtained for
protein extract preparation. The samples were immunoprecipitated (IP) with
antibodies anti Jak-2 (C, E) and Stat3 (D, F) and blotted (IB) with antiphosphoty-
rosine. Speciﬁc bands were quantiﬁed by densitometric analysis. In all experiments,
P < 0.05; *, vs. saline; &, vs. leptin; $, vs. PTP1B-ASO; Š, vs. PTP1B-ASO + leptin; f , vs.
TNF-a + PTP1B-ASO. Results are presented as means ± S.E.M.that the treatment with PTP1B-ASO decreased food intake
(10 ± 0.8 g) and potentiated the leptin-induced suppression of food
ingestion to 3.0 ± 0.7 g (P < 0.05 compared with leptin). In rats trea-
ted with PTP1B-ASO, TNF-a infusion completely blunt at the leptin
effect, suggesting that TNF-a does not require PTP1B to fully atten-
uate leptin’s effect (Fig. 3B).
The infusion of leptin increased Tyr-phosphorylation of Jak-2
and Stat3. The co-injection of TNF-a with leptin attenuated lep-
tin-stimulated Jak-2 and Stat3 tyrosine phosphorylation (Fig. 3C
and D). We next explored whether the deleterious effect of TNF-
a may be reversed through the reduction of hypothalamic PTP1B.
Rats treated with PTP1B-ASO showed a signiﬁcant increase in basal
and leptin-induced Jak-2 and Stat3 phosphorylation (Fig. 3E and F).
The reduction of hypothalamic PTP1B only partially reversed the
effect of TNF-a on leptin signaling at the level of Jak-2 and Stat3
tyrosine phosphorylation (Fig. 3E and F).5. Discussion
In the present study, we show that icv administration of TNF-a
increases PTP1B protein and activity in the hypothalamus, together
with reductions in insulin and leptin sensitivity and signaling. We
also show that TNF-a infusion increases phosphorylation of serine
residues and decreases tyrosine phosphorylation of PTP1B, which
may have a role in the control of PTP1B activity [29]. Our data also
reinforce the idea that TNF-a-induced insulin and leptin resistance
in hypothalamus, and that the inhibition of hypothalamic PTP1B
increases leptin/insulin signaling.
Leptin promotes inhibition of food intake, and PTP1B reduction
signiﬁcantly increases leptin-induced suppression of food inges-
tion. The administration of TNF-a alone promoted no change in
food intake, however, TNF-a followed by leptin signiﬁcantly re-
duced the anorexigenic effects of leptin. PTP1B controls leptin sig-
naling through dephosphorylation and inactivation of Jak-2 [8].
Our ﬁndings demonstrate that the increases in PTP1B expression
and activity in the hypothalamus of rats icv-treated with TNF-a
were associated with a decrease in Jak-2 tyrosine phosphorylation
levels. Since Jak-2 is a kinase that can mediate many steps down-
stream from leptin signaling, it is expected that a reduction in
Jak-2 phosphorylation will blunt leptin-induced Stat3 phosphory-
lation. In this regard, our data showed that the leptin resistance, in-
duced by TNF-a, in the rat hypothalamus was also characterized by
a less evident increase in Stat3 tyrosine phosphorylation induced
by leptin. These alterations were only partially reversed in TNF-
a-infused rats that were previously treated with PTP1B-ASO.
Similarly to leptin, insulin also inhibits food intake, and the
reduction in PTP1B signiﬁcantly increased this insulin effect.
Although the administration of TNF-a alone did not change food
intake, TNF-a followed by insulin signiﬁcantly reduced the insulin
anorexigenic effect. At the molecular level, there was a decrease in
insulin-induced IR tyrosine phosphorylation in the hypothalami of
TNF-a treated rats. Downstream, there was also a reduction in
insulin-induced IRS-1 tyrosine phosphorylation. These alterations
may have an important role in insulin resistance in hypothalami,
induced by TNF-a. Although, in obese animals, there is an increase
in IRS-1 serine phosphorylation in the hypothalamus [30,31],
which can contribute to insulin resistance, our data show that
the treatment of DIO rats with PTP1B-ASO reverses insulin resis-
tance in the hypothalamus of obese rats and also improves insulin
signaling in control rats [4]. Since IRS-1 is the substrate of the insu-
lin receptor, it is possible that the down regulation of PTP1B im-
proved insulin receptor tyrosine kinase activity, culminating with
an increase in insulin-induced IRS-1 tyrosine phosphorylation lev-
els and in Akt serine phosphorylation. Several studies have demon-
strated that insulin resistance of obesity is mediated by multiple
3184 P.K. Picardi et al. / FEBS Letters 584 (2010) 3179–3184mechanisms [30,31] and also insulin resistance induced by TNF-a
seems to be mediated by more than one mechanism [28]. Previous
data show that the lack of PTP1B confers protection against TNF-a-
induced insulin resistance [32]. Nieto-Vazquez et al., 2007, demon-
strated that, in PTP1B-deﬁcient myocytes, chronic exposure to
TNF-a does not impair insulin-induced glucose uptake or insulin
signaling. In addition, in PTP1B-/-mice, TNF-a is not able to induce
insulin resistance. It is important to mention that this protection
was observed in tissues other than the hypothalamus and with
higher doses of TNF-a. In the present study we investigated the ef-
fect of a very low dose of TNF-a in the hypothalamus of animals
previously treated with PTP1B-ASO. We may speculate that we
did not observe a clear effect of TNF-a through PTP1B, mainly in
consequence of the dose of TNF-a that we used. It is possible that
the ability of low doses of TNF-a to induce insulin resistance is
independent of PTP1B.
An important mechanism of insulin resistance in different tis-
sues is an increase in IRS-1 serine phosphorylation, speciﬁcally at
Ser307 [31]. This serine phosphorylation can be induced by many
serine kinases, but JNK and IKKb are certainly central in this pro-
cess and can be activated by TNF-a [17]. Our data showed that,
after icv infusion of a low dose of TNF-a there was a clear increase
in JNK and, IKKb phosphorylation and in the parallel in IRS-1Ser307
in the hypothalamus. These alterations may have an important role
in TNF-a-induced insulin resistance in the hypothalamus, and also
the insulin leptin resistance induced by this cytokine.
In conclusion, the results of the present study demonstrated
that the inhibition of hypothalamic PTP1B, induced by icv-treat-
ment with PTP1B-ASO, increased leptin/insulin signaling. The icv
infusion of a low dose of TNF-a-induced an increase in PTP1B pro-
tein expression/activity and attenuated insulin/leptin sensitivity/
signaling in the hypothalamus. However, TNF-a was able to com-
pletely blunt the leptin and insulin effect in rats treated with
PTP1B-ASO. These data suggest that, at least at this low dose,
TNF-a does not require PTP1B to fully attenuate the effects of lep-
tin and insulin. In addition, the data of the present study also show
that other mechanisms of insulin and leptin resistance such as an
increase in IRS-1Ser307, are also activated in the hypothalamus by
TNF-a.
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